Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field.


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
13 Jul 2023
Historique:
received: 12 04 2023
accepted: 31 05 2023
pmc-release: 13 07 2024
medline: 19 7 2023
pubmed: 19 7 2023
entrez: 19 7 2023
Statut: epublish

Résumé

In this study, we describe the rapid identification of potent binders for the WD40 repeat domain (WDR) of DCAF1. This was achieved by two rounds of iterative focused screening of a small set of compounds selected on the basis of internal WDR domain knowledge followed by hit expansion. Subsequent structure-based design led to nanomolar potency binders with a clear exit vector enabling DCAF1-based bifunctional degrader exploration.

Identifiants

pubmed: 37465299
doi: 10.1021/acsmedchemlett.3c00104
pmc: PMC10350940
doi:

Types de publication

Journal Article

Langues

eng

Pagination

949-954

Informations de copyright

© 2023 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

J Am Chem Soc. 2022 Oct 12;144(40):18688-18699
pubmed: 36170674
J Med Chem. 2007 Jan 11;50(1):74-82
pubmed: 17201411
Nature. 2014 Oct 30;514(7524):646-9
pubmed: 25156254
J Med Chem. 2023 Apr 13;66(7):5041-5060
pubmed: 36948210
Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18419-24
pubmed: 23091007
Gene. 2001 Jan 24;263(1-2):131-40
pubmed: 11223251
Nature. 2014 Jan 9;505(7482):234-8
pubmed: 24336198
J Proteome Res. 2017 Oct 6;16(10):3766-3773
pubmed: 28956604
J Chem Inf Model. 2008 Nov;48(11):2108-17
pubmed: 18991371
J Med Chem. 2017 Mar 23;60(6):2215-2226
pubmed: 28092155
PLoS One. 2017 Jan 10;12(1):e0169855
pubmed: 28072869
EMBO J. 2021 Nov 15;40(22):e108008
pubmed: 34595758
SLAS Discov. 2021 Apr;26(4):484-502
pubmed: 33143537
J Chem Inf Model. 2009 Feb;49(2):377-89
pubmed: 19434839
BMC Bioinformatics. 2009 Jun 02;10:168
pubmed: 19486540
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19266-71
pubmed: 20974918

Auteurs

Anna Vulpetti (A)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Philipp Holzer (P)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Niko Schmiedeberg (N)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Patricia Imbach-Weese (P)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Carole Pissot-Soldermann (C)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Gregory J Hollingworth (GJ)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Thomas Radimerski (T)

Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Claudio R Thoma (CR)

Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Therese-Marie Stachyra (TM)

Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Matthias Wojtynek (M)

Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Magdalena Maschlej (M)

Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Suzanne Chau (S)

Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Ansgar Schuffenhauer (A)

Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

César Fernández (C)

Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Martin Schröder (M)

Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Martin Renatus (M)

Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel 4002, Switzerland.

Classifications MeSH